Our research has demonstrated that oncogene HER2 (ErbB2)-upregulated HSF1 leads to enhanced glycolysis by transactivation of LDHA, a key enzyme in the glycolytic pathway, and the increase in glycolysis is related to cancer cell resistance to the HER2 targeting agent Herceptin 7, 112. The gene discussed is ERBB2; the disease is cancer.